SRSF2 mutations in epithelial ovarian cancer

 

  • Milena Sabrina Nicoloso Equally contributed
  • Monica Schiappacassi Equally contributed
  • Alessandra Dall’Acqua Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy.
  • Sara D’Andrea Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy.
  • Sara Benevol Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy.
  • Roberto Sorio Medical Oncology B, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy.
  • Vincenzo Canzonieri Pathology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy.
  • Giorgio Giorda Gynecology-Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy.
  • Gustavo Baldassarre Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy.
Keywords: epithelial ovarian cancer, platinum treatment, alternative splicing, SRSF2

Abstract

Resistance to platinum chemotherapy regimens represents a major obstacle in the successful treatment of epithelial ovarian cancer (EOC) patients. Among the molecular mechanism responsible for resistance to platinum, alternative splicing, which is induced upon platinum treatment, can control apoptosis by regulating the expression of apoptotic protein variants with opposite functions. Alterations in alternative splicing are found in tumors and can hinder apoptotic response. In the present study we sequenced SRSF2, a splicing factor that regulates Caspase-8 and Caspase-9 variants, in search of mutations that could possibly explain alternative mechanisms of platinum resistant in EOC.
Published
2017-12-15
Section
Clinical original article